Quarterly ResultMay 14, 2026, 08:56 AM
Dogwood Therapeutics Q1 Net Loss $5.0M; Halneuron® on track; SP16 IND; $100M Partnership
AI Summary
Dogwood Therapeutics announced its first quarter 2026 financial results, reporting a net loss attributable to common stockholders of $5.0 million, or $(0.15) per share. The company highlighted significant pipeline progress, with its Halneuron® Phase 2b trial on track for top-line results in fall 2026 and FDA acceptance of the SP16 IND Application. Additionally, Dogwood executed a worldwide development and commercialization partnership for legacy antiviral assets, with a potential value of up to $100 million.
Key Highlights
- Secured worldwide development and commercialization partnership for legacy antiviral assets, potentially valued up to $100M.
- Reported Q1 2026 net loss attributable to common stockholders of $5.0 million, down from $12.2 million in Q1 2025.
- Q1 2026 basic and diluted net loss per share was $(0.15), compared to $(8.45) in Q1 2025.
- Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathic Pain (CINP) is on track for top-line results in fall 2026.
- FDA accepted SP16 Investigational New Drug (IND) Application for chemotherapy-induced pain and neuropathy, with enrollment starting mid-2026.
- Cash and cash equivalents totaled $13.2 million as of March 31, 2026, providing operational runway into Q4 2026.
- Research and development expenses increased to $2.7 million in Q1 2026 from $2.4 million in Q1 2025.